Sachin Shridharani, MD

Articles by Sachin Shridharani, MD

Insights Into Positive Decision for Galderma's RelabotulinumtoxinA in Europe

ByEmma Andrus, Associate Editor,Sachin Shridharani, MD

August 12th 2024

Sachin Shridharani, MD, FACS, discusses the READY-1 and READY-2 clinical trials and positive support for Relfydess.

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

ByEmma Andrus, Assistant Editor,Sachin Shridharani, MD

September 26th 2023

Sachin Shridharani, MD, discusses the results of a recent Allergan Aesthetics study exploring the efficacy of onabotulinumtoxinA in treating platysma prominence.

Sachin Shridharani, MD

Articles by Sachin Shridharani, MD

Insights Into Positive Decision for Galderma's RelabotulinumtoxinA in Europe

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

Latest Updated Articles

Trending on Dermatology Times

Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial

Translational Takeaways: June 7, 2026

The Emerging Role of Oral Peptide Therapeutics in Dermatology

Dermatology Times Spot Test: June 7, 2026

New Immune-Mediated Therapies in AD, Alopecia Areata, and HS Presented at SDNP